PDF(921 KB)
Inhibitory effect of downregulating HMGB2 expression on epithelial-mesenchymal transition of liver cancer LM3 cells and its AKT/mTOR signaling pathway mechanism
Yanhong WEI,Chenxue YANG,Guangmin YANG,Shuai SONG,Ming LI,Haijiao YANG,Haifeng WEI
PDF(921 KB)
PDF(921 KB)
Inhibitory effect of downregulating HMGB2 expression on epithelial-mesenchymal transition of liver cancer LM3 cells and its AKT/mTOR signaling pathway mechanism
)Objective To discuss the effect of downregulating of high mobility group box protein 2 （HMGB2） expression on the biological behavior of the liver cancer cells and the epithelial-mesenchymal transition （EMT） process， and to clarify its mechanism. Methods The human liver cancer LM3 cells at logarithmic growth phase were divided into negative control group and HMGB2 RNA interference group （HMGB2 siRNA group）；the cells in two groups were transfected with RNA oligonucleotides（RNA oligos） with irrelevant sequences and RNA oligos designed to knock down HMGB2， and the Lipofectamine 2000 was regarded as the vector.The expression levels of HMGB2 mRNA and protein in the cells in two groups were detected by real-time fluorescence quantitative PCR （RT-qPCR） and Western blotting methods； cell scratch assay and Transwell chamber assay were used to detect the migration and invasion abilities of the cells in two groups； the expression levels of E-cadherin， N-cadherin， and Vimentin proteins and protein kinase B （AKT）/mammalian target of rapamycin （mTOR） pathway related proteins in the cells in two groups were detected by Western blotting method. Results Compared with negative control group， the expression levels of HMGB2 mRNA and protein in the cells in HMGB2 siRNA group were significantly decreased （P<0.05），the cell scratch healing rate was significantly decreased （P<0.01），the number of invasion cells was significantly decreased （P<0.01），and the expression level of E-cadherin protein in the cells was significantly increased （P<0.01）， while the expression levels of N-cadherin， Vimentin， mTOR， AKT， and phosphorylated AKT （p-AKT） proteins in the cells were significantly decreased （P<0.05 or P<0.01）. Conclusion Downregulating the expression of HMGB2 can reduce the migration and invasion abilities of the liver cancer LM3 cells and inhibit the EMT，and its mechanism may be related to regulating the expression of the AKT/mTOR pathway related proteins.
Liver carcinoma / High mobility group box protein 2 / Epithelial-mesenchymal transition / Cell migration / Cell invasion / Protein kinase B/mammalian target of rapamycin
R735.7
| 1 | MUKHERJEE A， VASQUEZ K M. Targeting chromosomal architectural HMGB proteins could be the next frontier in cancer therapy［J］. Cancer Res， 2020， 80（11）： 2075-2082. |
| 2 | NIU L R， YANG W L， DUAN L L， et al. Biological functions and theranostic potential of HMGB family members in human cancers［J］. Ther Adv Med Oncol， 2020， 12： 1758835920970850. |
| 3 | HAN X， ZHONG S Y， ZHANG P N， et al. Identification of differentially expressed proteins and clinicopathological significance of HMGB2 in cervical cancer［J］. Clin Proteomics， 2021， 18（1）： 2. |
| 4 | FANG J， GE X H， XU W J， et al. Bioinformatics analysis of the prognosis and biological significance of HMGB1， HMGB2， and HMGB3 in gastric cancer［J］. J Cell Physiol， 2020， 235（4）： 3438-3446. |
| 5 | 石小康， 丁佑铭， 汪 斌， 等. HMGB2基因表达对原发性肝癌患者临床病理和预后的影响［J］. 武汉大学学报（医学版）， 2019， 40（3）： 379-384. |
| 6 | LIU W W， CHENG J. LINC00974 sponges miR-33a to facilitate cell proliferation， invasion， and EMT of ovarian cancer through HMGB2 upregulation［J］. Genet Mol Biol， 2022， 45（1）： e20210224. |
| 7 | YU X C， LIU J B， TANG Q H， et al. Recent trends in the incidence and survival of stage Ⅰ liver cancer： a surveillance， epidemiology， and end results analysis［J］. Ann Med， 2022， 54（1）： 2785-2795. |
| 8 | 赫 捷， 陈万青， 沈洪兵. 中国人群肝癌筛查指南（2022，北京）［J］.临床肝胆病杂志，2022，38（8）： 1739-1758. |
| 9 | BENTLEY D R， DELOUKAS P， DUNHAM A，et al. The physical maps for sequencing human chromosomes 1，6，9，10，13，20 and Ⅹ［J］. Nature， 2001， 409（6822）： 942-943. |
| 10 | YUAN F， ZHAO Z T， JIA B， et al. TSN inhibits cell proliferation， migration， invasion， and EMT through regulating miR-874/HMGB2/β-catenin pathway in gastric cancer［J］. Neoplasma， 2020， 67（5）： 1012-1021. |
| 11 | KIM H K， KANG M A， KIM M S， et al. Transcriptional repression of high-mobility group box 2 by p21 in radiation-induced senescence［J］. Mol Cells， 2018， 41（4）： 362-372. |
| 12 | LI W， WANG Q X， FENG Q， et al. Oncogenic KSHV-encoded interferon regulatory factor upregulates HMGB2 and CMPK1 expression to promote cell invasion by disrupting a complex lncRNA-OIP5-AS1/miR-218-5p network［J］. PLoS Pathog， 2019， 15（1）： e1007578. |
| 13 | VOONG C K， GOODRICH J A， KUGEL J F. Interactions of HMGB proteins with the genome and the impact on disease［J］. Biomolecules，2021，11（10）：1451. |
| 14 | SHIROUZU S， SUGITA N， CHOIJOOKHUU N，et al. Pivotal role of High-Mobility Group Box 2 in ovarian folliculogenesis and fertility［J］. J Ovarian Res， 2022， 15（1）： 133. |
| 15 | MORINAGA H， MUTA Y， TANAKA T， et al. High-mobility group box 2 protein is essential for the early phase of adipogenesis［J］. Biochem Biophys Res Commun， 2021， 557： 97-103. |
| 16 | YANG S C， YE Z Y， WANG Z， et al. High mobility group box 2 modulates the progression of osteosarcoma and is related with poor prognosis［J］. Ann Transl Med， 2020， 8（17）： 1082. |
| 17 | QIU X， LIU W， ZHENG Y F， et al. Identification of HMGB2 associated with proliferation， invasion and prognosis in lung adenocarcinoma via weighted gene co-expression network analysis［J］. BMC Pulm Med， 2022， 22（1）： 310. |
| 18 | HE Z H， GUO F， HU X X， et al. Knockdown of HMGB2 inhibits proliferation and invasion of renal tumor cells via the p-38MAPK pathway［J］. Eur Rev Med Pharmacol Sci， 2020， 24（9）： 4729-4737. |
| 19 | GAO K L， LI M， ZHANG K P. Imperatorin inhibits the invasion and migration of breast cancer cells by regulating HMGB2［J］. J Biol Regul Homeost Agents， 2021， 35（1）： 227-230. |
| 20 | LI Y H， YIN Y L， HE Y， et al. SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway［J］. Biochem Biophys Res Commun， 2022， 637： 161-169. |
| 21 | YUN H E， HAN G H， KIM J， et al. NANOG regulates epithelial-mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV-3 and A2780 cells［J］. J Cell Mol Med， 2022， 26（20）： 5277-5291. |
| 22 | YUAN R， FAN Q M， LIANG X W， et al. Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition （EMT） in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways［J］. Chin Med， 2022， 17（1）： 24. |
| 23 | ZHU H， ZHAO N， JIANG M Z. Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway［J］. Biochem Cell Biol， 2021， 99（6）： 741-749. |
| 24 | LUO X Y， CAO M D， GAO F， et al. YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition［J］. Exp Hematol Oncol， 2021， 10（1）： 35. |
/
| 〈 |
|
〉 |
AI Summary
